Clinical Trials Logo

ISS Stage II Plasma Cell Myeloma clinical trials

View clinical trials related to ISS Stage II Plasma Cell Myeloma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT02727803 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Personalized NK Cell Therapy in CBT

Start date: May 19, 2016
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.